Skip to content

Evaluation of Sores Treatment by Oxygenotherapy

Evaluation of Sores Treatment by Oxygenotherapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03200353
Enrollment
31
Registered
2017-06-27
Start date
2017-04-10
Completion date
2023-12-31
Last updated
2023-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcer Venous

Brief summary

Patient with chronic wounds are selected to receive NATROX system ; it's a continous diffusion of oxygen therapy delivery system. This one is put on the wound during a consultation at the hospital and will be followed in home medical care. Every 2 days a nurse renew the application at home and patient recharge the system with oxygen every day. The complete treatment is prescribe for 4 weeks and at the end patient comes to hospital to have a consultation with the doctor.

Interventions

DEVICEsystem NATROX (device name)

system NATROX (device name) application on the wounds of lower limbs

Sponsors

Fondation Hôpital Saint-Joseph
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * accepted to participate * Patients followed in vascular medicine and entrusted to the home medical care for the bandages of chronic wounds with apathetic ulcers, not presenting of granulation tissue on their surface

Exclusion criteria

* infected ulcers * necrosed ulcers * Arterial ulcers requiring a revascularisation. * Ulcers whose surface is superior in 10x10 cm.

Design outcomes

Primary

MeasureTime frameDescription
number of patients received the entire treatment (3 to 4 weeks of oxygenotherapy) in home medical care4 weeksPatients who have received the entire treatment.

Secondary

MeasureTime frameDescription
percentage of patients who can receive skin graft after the therapy1-2 monthpatient eligible to skin graft after the therapy indicate the success of the NATROX system
percentage of patient who stopper the treatment4 weeksnumber of patients who have to stop the treatment because of non tolerability among all included patient

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026